Summary
AbbVie Inc. reported robust net revenues of $56.3 billion for the fiscal year 2024, marking a 3.7% increase driven by strong performance in its immunology, oncology, and neuroscience portfolios. Key growth drivers included significant revenue increases for Skyrizi (+51%) and Rinvoq (+50%), demonstrating strong market adoption and therapeutic differentiation. Despite the continued impact of Humira biosimilar competition, which saw a 37.6% revenue decline, AbbVie's diversified product base and strategic acquisitions, notably Cerevel Therapeutics and ImmunoGen, have positioned the company for continued growth. The company's financial results reflect substantial investments in research and development, a key strategic objective to fuel future innovation. AbbVie also continued to return capital to shareholders through increased dividends and share repurchases, underscoring its commitment to shareholder value.
Financial Highlights
56 data points| Revenue | $56.33B |
| Cost of Revenue | $16.90B |
| Gross Profit | $39.43B |
| SG&A Expenses | $14.75B |
| Operating Expenses | $47.20B |
| Operating Income | $9.14B |
| Interest Expense | $2.81B |
| Net Income | $4.28B |
| EPS (Basic) | $2.40 |
| EPS (Diluted) | $2.39 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.77B |
Key Highlights
- 1AbbVie reported total net revenues of $56.3 billion for 2024, a 3.7% increase compared to 2023, driven by strong growth in its key therapeutic areas.
- 2Skyrizi and Rinvoq demonstrated significant growth, with net revenues increasing by 51% and 50% respectively, highlighting their strong market performance.
- 3Humira experienced a substantial revenue decline of 37.6% due to ongoing biosimilar competition in the United States and internationally.
- 4The company completed two significant acquisitions in 2024: Cerevel Therapeutics for $8.7 billion to bolster its neuroscience pipeline and ImmunoGen for $9.8 billion to enhance its oncology portfolio, particularly in antibody-drug conjugates (ADCs).
- 5Research and Development (R&D) expenses increased significantly by 67% to $12.8 billion, reflecting substantial investments in pipeline advancement and new drug development.
- 6AbbVie's diluted earnings per share (EPS) was $2.39, which was impacted by significant non-cash charges including amortization of intangibles, impairment charges, and changes in fair value of contingent consideration liabilities.
- 7The company announced an increase in its quarterly dividend by 5.8% to $1.64 per share, demonstrating continued commitment to returning capital to shareholders.